Physician profile
Rene Vela
NPI 1346353414
$1,873.08
in general payments reported to CMS, 2019-2025
23 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $85.92 · 2021: $358 · 2022: $321 · 2023: $425 · 2024: $192 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bard Peripheral Vascular, INC. | $253.89 | 2019 | |
| Glaxosmithkline, LLC. | $231.63 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $187.98 | 2022-2024 | Xarelto |
| Astellas Pharma US INC | $98.87 | 2019-2022 | |
| Pfizer INC. | $88.10 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $81.52 | 2022-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $51.51 | 2022-2023 | |
| Amgen INC. | $46.38 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.35 | 2023-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $44.05 | 2023 | |
| Exact Sciences Corporation | $41.95 | 2023-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $35.79 | 2019-2020 | |
| Axsome Therapeutics, INC. | $32.95 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $31.62 | 2025 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.29 | 2023 | Rexulti |
| Abbvie INC. | $17.85 | 2025 | |
| Amarin Pharma, INC. | $15.05 | 2020 | |
| Lilly USA, LLC | $14.55 | 2022 | |
| Abbott Laboratories | $14.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.57 | 2023 | |
| Corium, LLC | $11.94 | 2023 | Adlarity |
| Elevate Oral Care | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Vela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.